Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: A CT analysis

Spine

Volumn 32, Issue 25, 2007, Pages 2885-2890

  Joseph, Vivek ^a   Rampersaud, Yoga Raja ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Bone morphogenetic protein; Minimally invasive surgery; Posterior lumbar interbody fusion; Transforaminal interbody fusion

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; AUTOGRAFT; BONE MALFORMATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; EPIDURAL SPACE; FEMALE; FOLLOW UP; HETEROTOPIC BONE FORMATION; HUMAN; INTERVERTEBRAL DISK; LUMBAR SPINE; MALE; OSSIFICATION; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SCORING SYSTEM; SPINE FUSION; VERTEBRAL CANAL; BACKACHE; BONE TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; DISABILITY; DRUG EFFECT; HETEROTOPIC OSSIFICATION; HOSPITALIZATION; INCIDENCE; LUMBAR VERTEBRA; METHODOLOGY; MIDDLE AGED; MINIMALLY INVASIVE SURGERY; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RADIOGRAPHY; SPINAL CORD DISEASE; SPINE DISEASE; TIME; TREATMENT OUTCOME;

ADULT; AGED; BACK PAIN; BONE MORPHOGENETIC PROTEINS; BONE TRANSPLANTATION; DISABILITY EVALUATION; EPIDURAL SPACE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSSIFICATION, HETEROTOPIC; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; SPINAL CORD DISEASES; SPINAL DISEASES; SPINAL FUSION; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 39049119326     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e31815b7596     Document Type: Article

References (18)

1. Boden SD, Zdeblick TA, Sandhu HS, et al. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 2000;25:376-81.
2. Kleeman TJ, Ahn UM, Talbot-Kleeman A. Laparoscopic anterior lumbar interbody fusion with rhBMP-2: a prospective study of clinical and radiographic outcomes. Spine 2001;26:2751-6.
3. Burkus JK, Transfeldt EE, Kitchel SH, et al. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine 2002;27:2396-408.
4. Burkus JK, Gornet MF, Dickman CA, et al. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 2002;15:337-49.
5. Burkus JK, Heim SE, Gornet MF, et al. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Tech 2003;16:113-22.
6. Burkus JK, Dorchak JD, Sanders DL. Radiographic assessment of interbody fusion using recombinant human bone morphogenetic protein type 2. Spine 2003;28:372-7.
7. Haid RW, Branch CL, Alexander JT, et al. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J 2004;4:527-39.
8. Schwender JD, Holly LT, Rouben DP, et al. Minimally invasive transforaminal lumbar interbody fusion (TLIF): technical feasibility and initial results. J Spinal Disord Tech 2005;18(suppl 1):1-6.
9. Mummaneni PV, Pan J, Haid RW, et al. Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg (Spine 1) 2004;1:19-23.
10. Villavicencio AT, Burneikiene S, Nelson EL, et al. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. J Neurosurg Spine 2005;3:436-43.
11. Kim KS, Yang TK, Lee JC. Radiological changes in the bone fusion site after posterior lumbar interbody fusion using carbon cages impacted with laminar bone chips: follow-up study over more than 4 years. Spine 2005;30:655-60.
12. Patel VV, Zhao Li, Wong P, et al. An in vitro and in vivo analysis of fibrin glue use to control bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth. Spine J 2006;6:397-404.
13. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 2002;27(suppl):40-8.
14. Meyer RA, Gruber HE, Howard BA, et al. Safety of recombinant human bone morphogenetic protein-2 after spinal laminectomy in the dog. Spine 1999;24:747-54.
15. Paramore CG, Lauryssen C, Rauzzino MJ, et al. The safety of OP-1 for lumbar fusion with decompression: a canine study. Neurosurgery 1999;44:1151-6.
16. McKay B, Sandhu HS. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 2002;27:S66-85.
17. Nakamura Y, Nakaya H, Saito N, et al. Coordinate expression of BMP-2, BMP receptors and Noggin in normal mouse spine. J Clin Neurosci 2006;13:250-6.
18. Glaser DL, Economides AN, Wang L, et al. In vivo somatic cell gene transfer of an engineered noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am 2003;85:2332-42.